Prevalence rates of low bone mineral density (BMD) and bone fractures are higher among HIV-infected adults compared with the general United States (US) population, but the relationship between BMD and incident fractures in HIV-infected persons has not been well described.
Methods
Dual energy X-ray absorptiometry (DXA) results of the femoral neck of the hip and clinical data were obtained prospectively during 2004-2012 from participants in two HIV cohort studies. Low BMD was defined by a T-score in the interval >-2.5 to <-1.0 (osteopenia) or ≤-2.5 (osteoporosis). We analysed the association of low BMD with risk of subsequent incident fractures, adjusted for sociodemographics, other risk factors and covariables, using multivariable proportional hazards regression.
Results
Among 1,006 participants analysed (median age 43 years [IQR 36–49], 83% male, 67% non-Hispanic white, median CD4+ T-cell count 461 cells/mm3 [IQR 311–658]), 36% (n=358) had osteopenia and 4% (n=37) osteoporosis; 67 had a prior fracture documented. During 4,068 person-years of observation after DXA scanning, 85 incident fractures occurred, predominantly rib/sternum (n=18), hand (n=14), foot (n=13) and wrist (n=11). In multivariable analyses, osteoporosis (adjusted hazard ratio [aHR] 4.02, 95% CI 2.02, 8.01) and current/prior tobacco use (aHR 1.59, 95% CI 1.02, 2.50) were associated with incident fracture.
Conclusions
In this large sample of HIV-infected adults in the US, low baseline BMD was significantly associated with elevated risk of incident fracture. There is potential value of DXA screening in this population.
References
1.
BrownT.T., QaqishR.B.Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review.AIDS2006; 20: 2165–2174.
2.
EscotaG.V., MondyK., BushT.High prevalence of low bone mineral density and substantial bone loss over 4 years among HIV-infected persons in the era of modern antiretroviral therapy.AIDS Res Hum Retroviruses2015; doi: 10.1089/aid.2015.0158.
3.
TebasP., PowderlyW.G., ClaxtonS.Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy.AIDS2000; 14: F63–F67.
4.
BedimoR., MaaloufN.M., ZhangS., DrechslerH., TebasP.Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents.AIDS2012; 26: 825–831.
5.
LookerA.C., WahnerH.W., DunnW.L.Updated data on proximal femur bone mineral levels of US adults.Osteoporos Int1998; 8: 468–489.
6.
McComseyG.A., KitchD., DaarE.S.Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.J Infect Dis2011; 203: 1791–1801.
7.
YinM.T., ShiQ., HooverD.R.Fracture incidence in HIV-infected women: results from the Women's Interagency HIV Study.AIDS2010; 24: 2679–2686.
8.
GibelliniD., De CrignisE., PontiC.HIV-1 triggers apoptosis in primary osteoblasts and HOBIT cells through TNFalpha activation.J Med Virol2008; 80: 1507–1514.
9.
HilemanC.O., LabbatoD.E., StorerN.J., TangprichaV., McComseyG.A.Is bone loss linked to chronic inflammation in antiretroviral-naive HIV-infected adults? A 48-week matched cohort study.AIDS2014; 28: 1759–1767.
10.
HansenA.B., GerstoftJ., KronborgG.Incidence of low and high-energy fractures in persons with and without HIV infection: a Danish population-based cohort study.AIDS2012; 26: 285–293.
11.
TriantV.A., BrownT.T., LeeH., GrinspoonS.K.Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system.J Clin Endocrinol Metab2008; 93: 3499–3504.
12.
YoungB., DaoC.N., BuchaczK., BakerR., BrooksJ.T.Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006.Clin Infect Dis2011; 52: 1061–1068.
13.
MoormanA.C., HolmbergS.D., MarloweS.I.Changing conditions and treatments in a dynamic cohort of ambulatory HIV patients: the HIV outpatient study (HOPS).Ann Epidemiol1999; 9: 349–357.
14.
VellozziC., BrooksJ.T., BushT.J.The study to understand the natural history of HIV and AIDS in the era of effective therapy (SUN Study).Am J Epidemiol2009; 169: 642–652.
15.
World Health Organization.Assessment of osteoporosis at the primary health care level. Geneva: Summary Report of a WHO Scientific Group; 2007. (Accessed 3 October 2015. Updated 2 October 2015.) Available from www.who.int/chp/topics/rheumatic/en/index.html.
16.
Assessment of fracture risk and its application to screening for post-menopausal osteoporosis.Report of a WHO Study Group.World Health Organization Technical Report Series1994; 843: 1–129.
GrijsenM.L., VrouenraetsS.M., WitF.W.Low bone mineral density, regardless of HIV status, in men who have sex with men.J Infect Dis2013; 207: 386–391.
19.
LiuA.Y., VittinghoffE., SellmeyerD.E.Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco.PLoS ONE2011; 6: e23688.
20.
MarshallD., JohnellO., WedelH.Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures.BMJ1996; 312: 1254–1259.
21.
National Osteoporosis Foundation.National Osteoporosis Foundation clinician's guide to prevention and treatment of osteoporosis 2013. (Accessed 7 April 2014. Updated 15 August 2014.) Available from http://nof.org/hcp/clinicians-guide.
Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents: Department of Health and Human Services; 2014. (Accessed 29 June 2014. Updated 3 October 2015.) Available from http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
25.
AbergJ.A., GallantJ.E., GhanemK.G., EmmanuelP., ZingmanB.S., HorbergM.A.Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America.Clin Infect Dis2014; 58: 1–10.
26.
BrownT.T., HoyJ., BorderiM.Recommendations for Evaluation and Management of Bone Disease in HIV.Clin Infect Dis2015; 60: 1242–1251.
27.
BattaloraL., BuchaczK., ArmonC.New fracture risk and FRAX 10-year probability of fracture in HIV-infected adults.Conference on Retroviruses and Opportunistic Infections. 3–6 March 2014, Boston, MA, USA. Abstract 276.
